Jounce Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2016 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Jounce Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2016 to Q4 2022.
  • Jounce Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending December 31, 2022 was $2.44M, a 12.5% decline year-over-year.
  • Jounce Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending December 31, 2022 was $10.3M, a 10.5% decline year-over-year.
  • Jounce Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $10.3M, a 10.5% decline from 2021.
  • Jounce Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $11.5M, a 17.5% increase from 2020.
  • Jounce Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2020 was $9.77M, a 1.69% increase from 2019.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2022 $10.3M $2.44M -$350K -12.5% Oct 1, 2022 Dec 31, 2022 10-K/A 2023-04-28
Q3 2022 $10.6M $2.56M -$366K -12.5% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-10
Q2 2022 $11M $2.44M -$492K -16.8% Apr 1, 2022 Jun 30, 2022 10-Q 2022-08-04
Q1 2022 $11.5M $2.83M +$4K +0.14% Jan 1, 2022 Mar 31, 2022 10-Q 2022-05-05
Q4 2021 $11.5M $2.79M +$742K +36.2% Oct 1, 2021 Dec 31, 2021 10-K/A 2023-04-28
Q3 2021 $10.7M $2.93M +$465K +18.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $10.3M $2.94M +$292K +11% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $9.98M $2.83M +$207K +7.91% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $9.77M $2.05M -$216K -9.54% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-02
Q3 2020 $9.99M $2.46M +$172K +7.51% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $9.82M $2.64M +$130K +5.17% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $9.69M $2.62M +$76K +2.99% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 $9.61M $2.27M -$179K -7.32% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 $9.79M $2.29M -$46K -1.97% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 $9.83M $2.51M +$153K +6.48% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-07
Q1 2019 $9.68M $2.54M +$274K +12.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q4 2018 $9.41M $2.44M +$1.13M +86.3% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 $8.28M $2.34M +$1.26M +117% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 $7.01M $2.36M +$1.32M +128% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $5.69M $2.27M +$915K +67.6% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q4 2017 $4.78M $1.31M +$43K +3.39% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-06
Q3 2017 $4.73M $1.07M -$1.55M -59.1% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 $6.28M $1.04M +$381K +58.2% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 $5.9M $1.35M +$913K +208% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 $4.99M $1.27M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-08
Q3 2016 $2.63M Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-13
Q2 2016 $655K Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 $440K Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.